DelveInsight’s, “Systemic Lupus Erythematosus Pipeline Insight, 2023,” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in the Systemic Lupus Erythematosus pipeline landscape. It covers the Systemic Lupus Erythematosus pipeline drug profiles, including Systemic Lupus Erythematosus clinical and nonclinical stage products. It also covers the Systemic Lupus Erythematosus therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Systemic Lupus Erythematosus Pipeline Report

• DelveInsight’s Systemic Lupus Erythematosus pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Systemic Lupus Erythematosus treatment.
• The leading companies working in the Systemic Lupus Erythematosus Market include Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve Therapeutics, Provention Bio, Pfizer, Novartis Pharmaceuticals, Neovacs, Merck KGaA, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Thearapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, and others.
• Promising Systemic Lupus Erythematosus Pipeline Therapies in the various stages of development include Anifrolumab, Medi-546, LY3471851, Baricitinib, Belimumab 10 mg/kg, and others.
• September 2023: RemeGen Co. Ltd announced a study of phase 1 clinical trials for Telitacicept 2.5 mg/kg. This is a multi-center, open-label, phase 1 study. The purpose of this study is to evaluate the pharmacokinetics (PK) of multiple doses of Telitacicept in subjects with childhood-onset systemic lupus erythematosus (cSLE) on a background of standard of care therapy and explore the safety and efficacy of Telitacicept in patients with cSLE.
• September 2023: UCB Pharma announced a study of phase 3 clinical trials for Dapirolizumab pegol. The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.

 

Request a sample and discover the recent advances in Systemic Lupus Erythematosus Treatment Drugs @ Systemic Lupus Erythematosus Pipeline Report

 

In the Systemic Lupus Erythematosus pipeline report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Systemic Lupus Erythematosus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Systemic Lupus Erythematosus Overview

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with multisystem involvement and is associated with significant morbidity and mortality. Genetic, immunological, endocrine, and environmental factors influence the loss of immunological tolerance against self-antigens leading to the formation of pathogenic autoantibodies that cause tissue damage through multiple mechanisms. Several immunopathogenic pathways play a role in the development of SLE.

 

Find out more about Systemic Lupus Erythematosus Therapeutics Assessment @ Systemic Lupus Erythematosus Preclinical and Discovery Stage Products

 

Systemic Lupus Erythematosus Emerging Drugs Profile

• Obinutuzumab (Gazyva): Roche
• Dapirolizumab pegol: UCB
• BIIB059: Biogen
• PRV 3279: Provention Bio
• ABBV-599: AbbVie

 

Systemic Lupus Erythematosus Pipeline Therapeutics Assessment

There are approx. 55+ key companies which are developing the Systemic Lupus Erythematosus therapies. The Systemic Lupus Erythematosus companies which have their Systemic Lupus Erythematosus drug candidates in the most advanced stage, i.e. Phase III include, Roche.

 

Learn more about the emerging Systemic Lupus Erythematosus Pipeline Therapies @ Systemic Lupus Erythematosus Clinical Trials Assessment

 

Scope of the Systemic Lupus Erythematosus Pipeline Report

• Coverage- Global
• Systemic Lupus Erythematosus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Systemic Lupus Erythematosus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Systemic Lupus Erythematosus Companies- Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve Therapeutics, Provention Bio, Pfizer, Novartis Pharmaceuticals, Neovacs, Merck KGaA, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Thearapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, and others.
• Systemic Lupus Erythematosus Pipeline Therapies- Anifrolumab, Medi-546, LY3471851, Baricitinib, Belimumab 10 mg/kg, and others.

 

Dive deep into rich insights for new drugs for Systemic Lupus Erythematosus treatment, Visit @ Systemic Lupus Erythematosus Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Systemic Lupus Erythematosus: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Systemic Lupus Erythematosus – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Obinutuzumab: Roche
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. PRV 3279: Provention Bio
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. E6742: Eisai
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Systemic Lupus Erythematosus – Collaborations Assessment- Licensing / Partnering / Funding
18. Systemic Lupus Erythematosus – Unmet Needs
19. Systemic Lupus Erythematosus – Market Drivers and Barriers
20. Appendix

 

For further information on the Systemic Lupus Erythematosus Pipeline Therapeutics, reach out to Systemic Lupus Erythematosus Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking